Lorajmine

Chemical compound
  • C01BA12 (WHO)
Identifiers
  • (17R,21β)-ajmalan-17,21-diol 17-chloroacetate
    OR
    (1R,9R,10S,13R,14R,16S,18S)-13-ethyl-8-methyl-14-hydroxy-8,15-diazahexacyclo [14.2.1.01,9.02,7.010,15.012,17]nonadeca-2(7),3,5-triene-18-yl chloroacetate
CAS Number
  • 47562-08-3
PubChem CID
  • 76957773
ChemSpider
  • 16735878 checkY
UNII
  • F96VX65849
ChEMBL
  • ChEMBL2111031
ECHA InfoCard100.051.185 Edit this at WikidataChemical and physical dataFormulaC22H27ClN2O3Molar mass402.92 g·mol−13D model (JSmol)
  • Interactive image
  • CCC1C2CC3C4C5(CC(C2C5C(=O)OCCl)N3C1O)C6=CC=CC=C6N4C
InChI
  • InChI=1S/C22H27ClN2O3/c1-3-11-12-8-15-19-22(13-6-4-5-7-14(13)24(19)2)9-16(25(15)21(11)27)18(12)20(22)28-17(26)10-23/h4-7,11-12,15-16,18-21,27H,3,8-10H2,1-2H3/t11-,12-,15-,16-,18?,19-,20+,21+,22+/m0/s1 checkY
  • Key:LAHDERDHXJFFJU-KBFYUGGWSA-N checkY
  (verify)

Lorajmine (17-monochloroacetylajmaline) is a drug that is a potent sodium channel blocker (more specifically, a class Ia antiarrhythmic agent) that was used for treating arrhythmia.[1][2][3] It is derived from ajmaline, an alkaloid from the roots of Rauvolfia serpentina, by synthetically adding a chloroacetate residue.

References

  1. ^ Medical Dictionary Online: Lorajmine
  2. ^ World Health Organization: ATC/DDD Index
  3. ^ Sanna G, Meoli P, Bianchini C, Rovelli F (1983). "Antiarrhythmic effectiveness of propafenone compared to lorajmine in ventricular arrhythmias. Controlled clinical trial". Giornale Italiano di Cardiologia. 13 (3): 145–51. PMID 6350090.
  • v
  • t
  • e
Channel blockers
class I
(Na+ channel blockers)
class Ia (Phase 0→ and Phase 3→)
class Ib (Phase 3←)
class Ic (Phase 0→)
class III
(Phase 3→, K+ channel blockers)
class IV
(Phase 4→, Ca2+ channel blockers)
Receptor agonists
and antagonists
class II
(Phase 4→, β blockers)
A1 agonist
M2
α receptors
Ion transporters
Na+/ K+-ATPase


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e